1. Home
  2. KODK vs RGNX Comparison

KODK vs RGNX Comparison

Compare KODK & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Eastman Kodak Company

KODK

Eastman Kodak Company

HOLD

Current Price

$8.05

Market Cap

834.8M

ML Signal

HOLD

Logo REGENXBIO Inc.

RGNX

REGENXBIO Inc.

HOLD

Current Price

$15.00

Market Cap

678.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KODK
RGNX
Founded
1880
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
834.8M
678.3M
IPO Year
N/A
2015

Fundamental Metrics

Financial Performance
Metric
KODK
RGNX
Price
$8.05
$15.00
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
$30.78
AVG Volume (30 Days)
1.1M
702.9K
Earning Date
11-06-2025
11-06-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,045,000,000.00
$161,318,000.00
Revenue This Year
N/A
$132.80
Revenue Next Year
N/A
$45.32
P/E Ratio
N/A
N/A
Revenue Growth
N/A
91.30
52 Week Low
$4.93
$5.04
52 Week High
$9.96
$15.80

Technical Indicators

Market Signals
Indicator
KODK
RGNX
Relative Strength Index (RSI) 44.12 60.86
Support Level $7.96 $12.87
Resistance Level $8.69 $15.80
Average True Range (ATR) 0.34 0.89
MACD -0.12 0.01
Stochastic Oscillator 5.53 75.43

Price Performance

Historical Comparison
KODK
RGNX

About KODK Eastman Kodak Company

Eastman Kodak Co is a United States-based company. It operates through several business segments; Print, Brand, and Advanced Materials and Chemicals. The Print segment which derives the majority of revenue includes products like digital offset plate offerings and computer-to-plate imaging solutions, high-quality digital printing solutions using electrically charged toner-based technology, production press systems, consumables, inkjet components, software and services. Geographically, the company generates revenue from the United States, Canada, Europe, Middle East and Africa, Asia Pacific, and Latin America.

About RGNX REGENXBIO Inc.

Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.

Share on Social Networks: